236 related articles for article (PubMed ID: 31795974)
1. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
[TBL] [Abstract][Full Text] [Related]
2. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
3. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
4. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
Alvarez-Breckenridge CA; Yu J; Price R; Wojton J; Pradarelli J; Mao H; Wei M; Wang Y; He S; Hardcastle J; Fernandez SA; Kaur B; Lawler SE; Vivier E; Mandelboim O; Moretta A; Caligiuri MA; Chiocca EA
Nat Med; 2012 Dec; 18(12):1827-34. PubMed ID: 23178246
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus.
Atsumi S; Matsumine A; Toyoda H; Niimi R; Iino T; Nakamura T; Matsubara T; Asanuma K; Komada Y; Uchida A; Sudo A
Int J Oncol; 2012 Sep; 41(3):893-902. PubMed ID: 22692919
[TBL] [Abstract][Full Text] [Related]
6. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
[TBL] [Abstract][Full Text] [Related]
7. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.
Miest TS; Frenzke M; Cattaneo R
Mol Ther; 2013 Nov; 21(11):2019-31. PubMed ID: 23913184
[TBL] [Abstract][Full Text] [Related]
8. Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
Son HA; Zhang L; Cuong BK; Van Tong H; Cuong LD; Hang NT; Nhung HTM; Yamamoto N; Toan NL
Cancer Invest; 2018 Feb; 36(2):106-117. PubMed ID: 29485292
[TBL] [Abstract][Full Text] [Related]
9. Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus.
Scheubeck G; Berchtold S; Smirnow I; Schenk A; Beil J; Lauer UM
Viruses; 2019 Jul; 11(7):. PubMed ID: 31284426
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
[TBL] [Abstract][Full Text] [Related]
11. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
12. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
13. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.
Lampe J; Bossow S; Weiland T; Smirnow I; Lehmann R; Neubert W; Bitzer M; Lauer UM
Gene Ther; 2013 Nov; 20(11):1033-41. PubMed ID: 23719065
[TBL] [Abstract][Full Text] [Related]
14. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.
Wilkinson MJ; Smith HG; Pencavel TD; Mansfield DC; Kyula-Currie J; Khan AA; McEntee G; Roulstone V; Hayes AJ; Harrington KJ
Int J Cancer; 2016 Sep; 139(6):1414-22. PubMed ID: 27116656
[TBL] [Abstract][Full Text] [Related]
16. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of measles virus oncolytic immunotherapy.
Pidelaserra-Martí G; Engeland CE
Cytokine Growth Factor Rev; 2020 Dec; 56():28-38. PubMed ID: 32660751
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
19. Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.
Yurttas C; Berchtold S; Malek NP; Bitzer M; Lauer UM
Hum Gene Ther Clin Dev; 2014 Jun; 25(2):85-96. PubMed ID: 24933569
[TBL] [Abstract][Full Text] [Related]
20. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
